FDA expands use of stool test from BD Diagnostics

01/12/2009 | Forbes

The FDA has allowed BD Diagnostics, a unit of Becton, Dickinson and Co., to sell a stool test for the "rapid detection" of a toxin that can cause Clostridium difficile infection. The BD GeneOhm Cdiff molecular test, which could remove the need for multiple screenings, is already approved for use in spotting methicillin-resistant Staphylococcus aureus.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA